<DOC>
	<DOCNO>NCT01814800</DOCNO>
	<brief_summary>This Phase III , multicenter , open-label study RI-002 administer intravenous infusion RI-002 ( IGIV ) every 21 28 day approximately 60 subject Primary Immunodeficiency Diseases ( PIDD ) .</brief_summary>
	<brief_title>Pharmacokinetics , Efficacy , Safety Study RI-002 ( IGIV ) Subjects With Primary Immunodeficiency Diseases ( PIDD )</brief_title>
	<detailed_description>Primary immunodeficiency disease ( PIDDs ) genetically determine disorder immune system result greatly enhance susceptibility infectious disease , autoimmunity malignancy . As subject PIDDs present infection , differential diagnosis initial investigation underlie immune defect typically guide clinical presentation . In subject PIDDs , individual infection necessarily severe occur normal host . Rather , clinical feature suggestive immune defect may recur and/or chronic nature infection common pathogen may result end organ damage , bronchiectasis . Several immune globulin product already approve FDA .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>To eligible participate study , subject must meet following criterion : 1 . Signed write informed consent specific assent form minor . 2 . Have diagnosis primary immunodeficiency disease . 3 . Be ≥ 2 year ≤ 75 year . 4 . Have body weight ≥ 12 kg screening . 5 . Have receive IGIV dose change &gt; 50 % mean dose mg/kg basis least 3 month prior study entry maintain trough serum Immunoglobulin G ( IgG ) level ≥ 500 mg/dL previous 2 assessment prior receive RI 002 . The trough level must least 300 mg/dL pretreatment serum IgG level . 6 . For female subject , nonchildbearing potential negative pregnancy test prior study start deem risk become pregnant adherence reliable contraceptive method duration study . Subjects must exclude meet follow criterion : 1 . Have know hypersensitivity immunoglobulin excipient RI002 . 2 . Have history severe anaphylactic anaphylactoid reaction blood bloodderived product . 3 . Have specific Immunoglobulin A ( IgA ) deficiency , history allergic reaction product contain IgA demonstrable antibody IgA . 4 . Have uncompensated hemodynamically significant congenital heart disease . 5 . Have medical condition know cause secondary immune deficiency . 6 . Have significant Tcell deficiency deficiency granulocyte number function . 7 . Have significant renal impairment history acute renal failure . 8 . Have abnormal liver function . 9 . Be receive chronic anticoagulation therapy . 10 . Have history deep vein thrombosis ( DVT ) , thrombotic thromboembolic event , increase risk thrombotic event . 11 . Current daily use follow medication : corticosteroid ( &gt; 7.5 mg ( equivalent dose mg/kg basis ) prednisone equivalent per day &gt; 30 day ) immunomodulatory drug immunosuppressive drug ( exclude topical pimecrolimus ( Elidel ) tacrolimus ( Protopic ) ) 12 . Administration hyperimmune specialty high titer immunoglobulin product . 13 . Have uncontrollable arterial hypertension . 14 . Have history hemolysis positive Coombs test undergo treatment IGIV therapy . 15 . Be morbidly obese indicate Body Mass Index ( BMI ) ≥ 40 16 . Have receive blood product ( Immunoglobulin G ) within 3 month prior screen . 17 . Have receive Respiratory Syncytial Virus ( RSV ) specific product , include palivizumab ( Synagis® ) within 3 month prior screen . 18 . Have abuse alcohol , opiates , psychotropic agent , chemical drug within past 12 month . 19 . Have condition abnormal laboratory assessment judge investigator preclude participation study . 20 . Are currently pregnant nursing . 21 . Have hepatitis A , B , C .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PIDD , PID , humoral immunity , antibody deficiency</keyword>
</DOC>